Dosage calculator
Menu ☰
← All peptide guides

Energy & ageing · Primarily preclinical

MOTS-c

Fictional visual analogy: mitochondrial courier
Fictional visual analogy: mitochondrial courier

MOTS-c is unusual because it is a mitochondrial-derived peptide - essentially a message linked to the little energy-producing structures inside our cells.

Educational guide · evidence level shown throughout

THE ONE-MINUTE PUB CHAT

THE TELEGRAM FROM YOUR MITOCHONDRIA

MOTS-c is unusual because it is a mitochondrial-derived peptide – essentially a message linked to the little energy-producing structures inside our cells.

Research connects MOTS-c with metabolic stress, glucose handling, exercise responses and pathways such as AMPK, particularly in animal and laboratory work.

Imagine your mitochondria have spent years silently generating energy in the basement. Then one day they send upstairs a telegram saying, 'Could everyone please stop behaving as if fuel is unlimited?'

That is the appeal of MOTS-c: it looks like part of the conversation between cellular energy status and the rest of the body.

Human observations around exercise add interest, but most of the exciting intervention claims remain preclinical.

Fascinating telegram. We are still translating the handwriting.

The joke is an analogy, not a clinical claim.

Overview illustrationQuick orientation

Evidence update: 6 October 2026

What is MOTS-c?

MOTS-c is unusual because it is a mitochondrial-derived peptide - essentially a message linked to the little energy-producing structures inside our cells.

What it is / targetsMitochondrial-derived peptide linked to AMPK/metabolic stress signalling and exercise adaptation in preclinical research.
What researchers studiedStrongest evidence is cell/animal; human observational and exercise-related work is early.
Evidence snapshotPrimarily preclinical

Why people are interested

The potential benefits, unpacked.

Here are the goals and claims that bring readers to this guide. The evidence note shows which part is demonstrated, early research or still a question.

The headline interest

Strongest evidence is cell/animal; human observational and exercise-related work is early.

What the mechanism suggests

Mitochondrial-derived peptide linked to AMPK/metabolic stress signalling and exercise adaptation in preclinical research.

What still needs proving

The key question is whether the claimed benefit has been demonstrated in controlled human studies using the same compound, route and population.

What is it actually doing?

Mitochondrial-derived peptide linked to AMPK/metabolic stress signalling and exercise adaptation in preclinical research.

The important distinction is between changing a biomarker or pathway and producing a meaningful outcome that people can feel, measure or sustain.

Mechanism is not outcome. A biologically interesting pathway does not by itself prove a useful effect in people.
Results illustrationResults at a glance

Human evidence

What did the studies actually find?

1 highlighted

Human study deep dive

The most informative human evidence we could identify is translated below, with the original source linked.

Study evidence illustrationStudy evidence

Study deep dives

The important studies, translated into normal English.

Each synopsis keeps the trial design, actual results and limitations together. Graphs below are redrawn from the cited numerical results so you can see the size of the effect without having to decode a journal figure.

Exercise-induced MOTS-c study — Nature Communications 2021

Human exercise observations plus cell and mouse experiments

The paper found MOTS-c responds to exercise biology in humans and demonstrated improved physical performance and metabolic adaptation in mice. It did not test MOTS-c injections as an exercise drug in a human RCT.

Peptalk takeaway

Interesting human biology plus strong preclinical work is not the same as demonstrated human treatment efficacy.

What it doesn't prove: Most intervention evidence was in mice; no established human therapeutic dose follows from this paper.

Read the original study / source ↗
Dose comparison illustrationDosing reference

Research, licensed & reported protocols

What doses and schedules are actually documented?

Human research or licensed product information is separated from clinic and community practice. These are source-attributed reference protocols, not personalised dosing recommendations.

Human research / licensed or product dosing

Protocol / contextAmount & frequencyDurationTitrationEvidence
Human evidencePublished human work mainly measures endogenous MOTS-c responses; no completed human dose-finding/efficacy trial establishing an administered dose——No validated human administration regimen

Community / clinic / specialist protocols

PatternAmount & frequencyCycleProgressionStatus
20-day pulsed convention5 mg SC every 5 days20 days / 4 doses; often repeated a few times/yearFixedClinic/community
Intensive convention5 mg SC 3× weekly4–6 weeksFixedCommunity
Higher intermittent10 mg SC 1–3× weekly4–10 weeks depending sourceUsually fixedCommunity
8-week phased5 mg 3× weekly weeks 1–4 →5 mg weekly weeks 5–88 weeks; ~4-week breakFrequency taperCommunity database
Daily microdose ladder200→400→600→800→1000 mcg daily2 weeks at each step200 mcg increments every 2 Specia weeks evidenlist/community; weak ce
Evidence reality check

The administered human dose is unknown. Online 5–10 mg schedules are community/clinic conventions, not clinical-trial doses. PP should say this prominently.

Evidence checked: 7 October 2026

Routes and formulations matter. A topical study does not validate injection; an IV research dose does not establish a fixed SC dose; and evidence for one molecular form must not be silently transferred to another.

Community reports illustrationCommunity reports

Community reports

What are people actually doing?

Anecdote, not evidence. These examples document community practice and experiences. They do not establish safety, efficacy or an appropriate dose.

Community experience exists, but is anecdotal

Forums discuss schedules, effects and side effects, but posts are uncontrolled self-reports and product identity may be uncertain. Use them to understand what people report—not to estimate efficacy or establish a dose.

View the discussion on Reddit ↗
Safety illustrationSafety and uncertainty

Safety, side effects & what we don't know

Not an established treatment for energy, ageing or metabolic disease.

Product identity, sterility and concentration are additional uncertainties for unlicensed research products. Evidence from an approved medicine or a clinical trial should not be transferred automatically to a differently sourced product.

Educational information only. Research compounds, trial protocols and community reports should not be treated as individual medical advice.
Questions illustrationQuestions

Questions worth asking

What is the strongest evidence here?

Interesting human biology plus strong preclinical work is not the same as demonstrated human treatment efficacy.

Does a biological mechanism prove the claimed benefit?

No. Receptor activity, cell effects and animal results can justify research, but controlled human outcomes are a separate evidential step.

Is the research protocol a recommended dose?

No. The site reports study protocols to explain the evidence. It does not turn them into personalised self-use instructions.

Sources illustrationPrimary sources

Studies, sources & further reading

External links are provided for transparency and further reading. Linking to a study, discussion or organisation does not mean Peptides Peptalk endorses every conclusion on that page.